Genmab A/S (GMAB) P/E Ratio History
ExpensiveTrading at 18.9x vs 5Y avg 5.3x · 100th percentile · Material premium to history · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Genmab A/S (GMAB) trades at a price-to-earnings ratio of 18.9x, with a stock price of $29.18 and trailing twelve-month earnings per share of $4.09.
The current P/E is 258% above its 5-year average of 5.3x. Over the past five years, GMAB's P/E has ranged from a low of 1.7x to a high of 10.7x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, GMAB trades at a 19% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, GMAB trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GMAB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GMAB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
GMAB P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $70B | 16.3Lowest | 2.58 | +8% | |
| $24B | 18.4 | - | +4173%Best | |
| $14B | 20.5 | 0.40Best | +58% | |
| $10B | 31.9 | 1.39 | -25% | |
| $450B | 107.4 | - | -1% | |
| $118B | 16.8 | - | +178% | |
| $318B | 17.7 | 0.83 | +8% | |
| $8B | 162.6 | - | +287% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
GMAB Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $26.83 | $4.20 | 6.4x | -21% |
| FY2025 Q4 | Dec 31 2025 | $30.80 | $4.43 | 7.0x | -14% |
| FY2025 Q3 | - | $30.67 | $10.37 | 3.0x | -63% |
| FY2025 Q2 | Jun 30 2025 | $20.66 | $11.67 | 1.8x | -78% |
| FY2025 Q1 | Mar 31 2025 | $19.58 | $10.42 | 1.9x | -77% |
| FY2024 Q4 | - | $20.87 | $12.13 | 1.7x | -79% |
| FY2024 Q3 | Sep 30 2024 | $24.38 | $7.11 | 3.4x | -58% |
| FY2024 Q2 | Jun 30 2024 | $25.13 | $8.39 | 3.0x | -63% |
| FY2024 Q1 | Mar 31 2024 | $29.91 | $8.28 | 3.6x | -55% |
| FY2023 Q4 | Dec 31 2023 | $31.84 | $6.58 | 4.8x | -40% |
| FY2023 Q3 | Sep 30 2023 | $35.27 | $6.49 | 5.4x | -33% |
| FY2023 Q2 | Jun 30 2023 | $38.01 | $7.18 | 5.3x | -35% |
| FY2023 Q1 | Mar 31 2023 | $37.76 | $7.99 | 4.7x | -42% |
| FY2022 Q4 | Dec 31 2022 | $42.38 | $8.38 | 5.1x | -37% |
| FY2022 Q3 | Sep 30 2022 | $32.13 | $8.58 | 3.7x | -54% |
| FY2022 Q2 | - | $32.49 | $6.01 | 5.4x | -33% |
| FY2022 Q1 | - | $36.18 | $3.60 | 10.1x | +24% |
| FY2021 Q4 | Dec 31 2021 | $39.56 | $4.55 | 8.7x | +7% |
| FY2021 Q3 | - | $43.70 | $4.35 | 10.0x | +24% |
| FY2021 Q2 | Jun 30 2021 | $40.83 | $3.80 | 10.7x | +33% |
| FY2021 Q1 | Mar 31 2021 | $32.83 | $8.48 | 3.9x | -52% |
| FY2020 Q4 | - | $40.66 | $7.23 | 5.6x | -30% |
| FY2020 Q3 | Sep 30 2020 | $36.61 | $8.65 | 4.2x | -48% |
| FY2020 Q2 | - | $33.89 | $8.68 | 3.9x | -52% |
| FY2020 Q1 | - | $21.19 | $3.68 | 5.8x | -29% |
| FY2019 Q4 | - | $22.33 | $3.39 | 6.6x | -19% |
| FY2019 Q3 | Sep 30 2019 | $20.26 | $2.43 | 8.3x | +3% |
| FY2019 Q2 | Jun 30 2019 | $18.47 | $1.89 | 9.8x | +21% |
| FY2019 Q1 | Mar 31 2019 | $17.44 | $2.17 | 8.0x | -1% |
| FY2018 Q4 | Dec 31 2018 | $16.48 | $2.37 | 7.0x | -14% |
| FY2018 Q3 | Sep 30 2018 | $15.75 | $2.29 | 6.9x | -15% |
| FY2018 Q2 | Jun 30 2018 | $15.32 | $1.99 | 7.7x | -5% |
| FY2018 Q1 | Mar 31 2018 | $21.68 | $2.07 | 10.5x | +29% |
| FY2017 Q4 | Dec 31 2017 | $16.58 | $1.78 | 9.3x | +15% |
| FY2017 Q3 | Sep 30 2017 | $22.11 | $1.88 | 11.8x | +46% |
| FY2017 Q2 | Jun 30 2017 | $21.38 | $2.20 | 9.7x | +20% |
| FY2017 Q1 | Mar 31 2017 | $19.36 | $1.97 | 9.8x | +22% |
| FY2016 Q4 | Dec 31 2016 | $16.58 | $1.92 | 8.6x | +7% |
| FY2016 Q3 | Sep 30 2016 | $17.11 | $1.21 | 14.1x | +75% |
| FY2016 Q2 | - | $18.26 | $1.13 | 16.1x | +100% |
| FY2016 Q1 | - | $13.91 | $0.89 | 15.7x | +94% |
| FY2015 Q4 | - | $13.40 | $1.27 | 10.6x | +31% |
| FY2015 Q3 | Sep 30 2015 | $9.10 | $0.74 | 12.3x | +53% |
| FY2015 Q2 | - | $8.67 | $0.79 | 11.0x | +36% |
| FY2015 Q1 | - | $7.55 | $0.71 | 10.6x | +31% |
| FY2014 Q4 | Dec 31 2014 | $5.86 | $0.53 | 11.0x | +36% |
| FY2014 Q3 | - | $4.21 | $0.52 | 8.0x | -1% |
| FY2014 Q2 | Jun 30 2014 | $4.22 | $0.25 | 16.6x | +105% |
| FY2014 Q1 | Mar 31 2014 | $4.17 | $0.25 | 16.7x | +106% |
| FY2013 Q4 | - | $3.91 | $0.21 | 18.6x | +130% |
Average P/E for displayed period: 8.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GMAB — Frequently Asked Questions
Quick answers to the most common questions about buying GMAB stock.
What is GMAB's P/E ratio?
Genmab A/S (GMAB) trailing twelve-month P/E ratio is 18.9x, based on TTM diluted EPS of $4.09. The 5-year average P/E is 5.3x and the historical range spans 1.7x to 10.7x.
Is GMAB stock overvalued or undervalued?
GMAB trades at 18.9x P/E, above its 5-year average of 5.3x. The 100th percentile ranking within the 1.7x–10.7x historical range indicates a premium to historical valuation.
Is GMAB stock expensive?
Yes, GMAB is expensive relative to its own history. The current P/E of 18.9x is above the 5-year average of 5.3x. The stock sits at the 100th percentile of its 5-year valuation range.
What is GMAB's historical P/E range?
Over the past 5 years, GMAB's P/E ratio has ranged from 1.7x to 10.7x, with a median of 5.1x and an average of 5.3x. The current P/E of 18.9x places the stock at the 100th percentile of this range. Full historical data spans 2013–2026.
How does GMAB's P/E compare to the S&P 500?
GMAB trades at 18.9x P/E versus the S&P 500 median of 25.9x. The 27% discount to the market suggests lower growth expectations or perceived higher risk.
How does GMAB's valuation compare to Healthcare peers?
Genmab A/S P/E of 18.9x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is GMAB's PEG ratio?
GMAB PEG ratio is N/A, based on a P/E of 18.9x and EPS growth of -87.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is GMAB's earnings yield?
GMAB earnings yield is 5.28%, the inverse of its 18.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.